Platelet von Willebrand factor: Sweet resistance

Blood

Volumn 122, Issue 25, 2013, Pages 4006-4007

  Lenting, Peter J ^a   Denis, Cécile V ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLOOD GROUP ABO SYSTEM; CELL GRANULE; ENDOTHELIUM CELL; GLYCOSYLATION; HEMOSTASIS; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIALYLATION; THROMBOCYTE;

EID: 84891048715     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533174     Document Type: Review

References (15)

1. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-175
2. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364-1372
3. Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-u and impaired receptor-mediated activation of GP2b-3a and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood. 2004;103(3):948-954
4. Rao AK. Inherited platelet function disorders. In: Rao AK, ed. Hematology/Oncology Clinics of North America: Disorders of the Platelets. Philadelphia, PA: Elsevier; 2013: 585-611
5. Kaur G, Jalagadugula G, Mao G, Rao AK. RUNX1/ core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood. 2010;115(15):3128-3135
6. Sun L, Gorospe JR, Hoffman EP, Rao AK. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost. 2007;5(1): 146-154
7. Jalagadugula G, Mao G, Kaur G, Goldfinger LE, Dhanasekaran DN, Rao AK. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood. 2010;116(26):6037-6045
8. McGrath RT, van den Biggelaar M, Byrne B, et al. Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood. 2013;122(25):4107-4110
9. Hennet T. Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochim Biophys Acta. 2012;1820(9):1306-1317
10. Gralnick HR, Rick ME, McKeown LP, et al. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. Blood. 1986;68(1):58-61
11. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10(8):1646-1652
12. McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor - structure, function and biological importance. Br J Haematol. 2010;148(6): 834-843
13. Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol. 1994;88(3):582-591
14. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1):33-40
15. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor - too sweet for their own good. Haemophilia. 2010;16(Suppl 5): 194-199